View Agent
| Agent Info | |
| Agent: | dovitinib |
| Synonyms: | Chir 258;CHIR-258;TKI-258;TKI-258, Dovitinib, CHIR258, TKI258;4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one |
| Drug Status For Certain Diseases: | Advanced or metastatic renal cell cancer(phase I/II) |
| Classification: | an oral tyrosine-kinase inhibitor that inhibits FGF receptor (FGFR), VEGFR, and platelet-derived growth factor receptor (PDGFR). |
| Target: | Fibroblast growth factor receptor 3 Platelet-derived growth factor receptor |
| KEGG Pathway: | Regulation of actin cytoskeleton Ras signaling pathway Signaling pathways regulating pluripotency of stem cells MAPK signaling pathway Rap1 signaling pathway PI3K-Akt signaling pathway Bladder cancer Pathways in cancer Central carbon metabolism in cancer MicroRNAs in cancer Endocytosis |
| Wiki Pathway: | Endochondral Ossification Neural Crest Differentiation Signaling by FGFR Regulation of Actin Cytoskeleton Bladder Cancer |